Literature DB >> 29097371

Anti-CD19 resistance can "stem" from progenitors.

Nirali N Shah1, Terry J Fry1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29097371      PMCID： PMC5669210          DOI： 10.1182/blood-2017-09-804070

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  Clonal architecture of secondary acute myeloid leukemia.

Authors:  Matthew J Walter; Dong Shen; Li Ding; Jin Shao; Daniel C Koboldt; Ken Chen; David E Larson; Michael D McLellan; David Dooling; Rachel Abbott; Robert Fulton; Vincent Magrini; Heather Schmidt; Joelle Kalicki-Veizer; Michelle O'Laughlin; Xian Fan; Marcus Grillot; Sarah Witowski; Sharon Heath; John L Frater; William Eades; Michael Tomasson; Peter Westervelt; John F DiPersio; Daniel C Link; Elaine R Mardis; Timothy J Ley; Richard K Wilson; Timothy A Graubert
Journal:  N Engl J Med       Date:  2012-03-14       Impact factor: 91.245

2.  Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.

Authors:  Shalini C Reshmi; Richard C Harvey; Kathryn G Roberts; Eileen Stonerock; Amy Smith; Heather Jenkins; I-Ming Chen; Marc Valentine; Yu Liu; Yongjin Li; Ying Shao; John Easton; Debbie Payne-Turner; Zhaohui Gu; Thai Hoa Tran; Jonathan V Nguyen; Meenakshi Devidas; Yunfeng Dai; Nyla A Heerema; Andrew J Carroll; Elizabeth A Raetz; Michael J Borowitz; Brent L Wood; Anne L Angiolillo; Michael J Burke; Wanda L Salzer; Patrick A Zweidler-McKay; Karen R Rabin; William L Carroll; Jinghui Zhang; Mignon L Loh; Charles G Mullighan; Cheryl L Willman; Julie M Gastier-Foster; Stephen P Hunger
Journal:  Blood       Date:  2017-04-13       Impact factor: 22.113

3.  Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.

Authors:  Rebecca Gardner; David Wu; Sindhu Cherian; Min Fang; Laïla-Aïcha Hanafi; Olivia Finney; Hannah Smithers; Michael C Jensen; Stanley R Riddell; David G Maloney; Cameron J Turtle
Journal:  Blood       Date:  2016-02-23       Impact factor: 22.113

4.  Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.

Authors:  Elena Sotillo; David M Barrett; Kathryn L Black; Asen Bagashev; Derek Oldridge; Glendon Wu; Robyn Sussman; Claudia Lanauze; Marco Ruella; Matthew R Gazzara; Nicole M Martinez; Colleen T Harrington; Elaine Y Chung; Jessica Perazzelli; Ted J Hofmann; Shannon L Maude; Pichai Raman; Alejandro Barrera; Saar Gill; Simon F Lacey; Jan J Melenhorst; David Allman; Elad Jacoby; Terry Fry; Crystal Mackall; Yoseph Barash; Kristen W Lynch; John M Maris; Stephan A Grupp; Andrei Thomas-Tikhonenko
Journal:  Cancer Discov       Date:  2015-10-29       Impact factor: 39.397

5.  Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as a potential mechanism of resistance to blinatumomab therapy.

Authors:  Inga Nagel; Marius Bartels; Johannes Duell; Hans-Heinrich Oberg; Sandra Ussat; Henrike Bruckmueller; Oliver Ottmann; Heike Pfeifer; Heiko Trautmann; Nicola Gökbuget; Almuth Caliebe; Dieter Kabelitz; Michael Kneba; Heinz-August Horst; Dieter Hoelzer; Max S Topp; Ingolf Cascorbi; Reiner Siebert; Monika Brüggemann
Journal:  Blood       Date:  2017-08-21       Impact factor: 22.113

Review 6.  Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers.

Authors:  Robbie G Majzner; Sabine Heitzeneder; Crystal L Mackall
Journal:  Cancer Cell       Date:  2017-03-30       Impact factor: 31.743

7.  Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.

Authors:  Marco Ruella; David M Barrett; Saad S Kenderian; Olga Shestova; Ted J Hofmann; Jessica Perazzelli; Michael Klichinsky; Vania Aikawa; Farzana Nazimuddin; Miroslaw Kozlowski; John Scholler; Simon F Lacey; Jan J Melenhorst; Jennifer J D Morrissette; David A Christian; Christopher A Hunter; Michael Kalos; David L Porter; Carl H June; Stephan A Grupp; Saar Gill
Journal:  J Clin Invest       Date:  2016-08-29       Impact factor: 14.808

8.  Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.

Authors:  Kathryn G Roberts; Yongjin Li; Debbie Payne-Turner; Richard C Harvey; Yung-Li Yang; Deqing Pei; Kelly McCastlain; Li Ding; Charles Lu; Guangchun Song; Jing Ma; Jared Becksfort; Michael Rusch; Shann-Ching Chen; John Easton; Jinjun Cheng; Kristy Boggs; Natalia Santiago-Morales; Ilaria Iacobucci; Robert S Fulton; Ji Wen; Marcus Valentine; Cheng Cheng; Steven W Paugh; Meenakshi Devidas; I-Ming Chen; Shalini Reshmi; Amy Smith; Erin Hedlund; Pankaj Gupta; Panduka Nagahawatte; Gang Wu; Xiang Chen; Donald Yergeau; Bhavin Vadodaria; Heather Mulder; Naomi J Winick; Eric C Larsen; William L Carroll; Nyla A Heerema; Andrew J Carroll; Guy Grayson; Sarah K Tasian; Andrew S Moore; Frank Keller; Melissa Frei-Jones; James A Whitlock; Elizabeth A Raetz; Deborah L White; Timothy P Hughes; Jaime M Guidry Auvil; Malcolm A Smith; Guido Marcucci; Clara D Bloomfield; Krzysztof Mrózek; Jessica Kohlschmidt; Wendy Stock; Steven M Kornblau; Marina Konopleva; Elisabeth Paietta; Ching-Hon Pui; Sima Jeha; Mary V Relling; William E Evans; Daniela S Gerhard; Julie M Gastier-Foster; Elaine Mardis; Richard K Wilson; Mignon L Loh; James R Downing; Stephen P Hunger; Cheryl L Willman; Jinghui Zhang; Charles G Mullighan
Journal:  N Engl J Med       Date:  2014-09-11       Impact factor: 91.245

9.  CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis.

Authors:  Jeannette Fischer; Claudia Paret; Khalifa El Malki; Francesca Alt; Arthur Wingerter; Marie A Neu; Bettina Kron; Alexandra Russo; Nadine Lehmann; Lea Roth; Eva-M Fehr; Sebastian Attig; Alexander Hohberger; Thomas Kindler; Jörg Faber
Journal:  J Immunother       Date:  2017-06       Impact factor: 4.456

10.  CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity.

Authors:  Elad Jacoby; Sang M Nguyen; Thomas J Fountaine; Kathryn Welp; Berkley Gryder; Haiying Qin; Yinmeng Yang; Christopher D Chien; Alix E Seif; Haiyan Lei; Young K Song; Javed Khan; Daniel W Lee; Crystal L Mackall; Rebecca A Gardner; Michael C Jensen; Jack F Shern; Terry J Fry
Journal:  Nat Commun       Date:  2016-07-27       Impact factor: 14.919
  10 in total
  2 in total

1.  CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.

Authors:  Vinodh Pillai; Kavitha Muralidharan; Wenzhao Meng; Asen Bagashev; Derek A Oldridge; Jaclyn Rosenthal; John Van Arnam; Jos J Melenhorst; Diwakar Mohan; Amanda M DiNofia; Minjie Luo; Sindhu Cherian; Jonathan R Fromm; Gerald Wertheim; Andrei Thomas-Tikhonenko; Michele Paessler; Carl H June; Eline T Luning Prak; Vijay G Bhoj; Stephan A Grupp; Shannon L Maude; Susan R Rheingold
Journal:  Blood Adv       Date:  2019-11-26

Review 2.  CAR T cell therapy: newer approaches to counter resistance and cost.

Authors:  Rajesh Kumar Yadav; Asgar Ali; Santosh Kumar; Alpana Sharma; Basab Baghchi; Pritanjali Singh; Sushmita Das; Chandramani Singh; Sadhana Sharma
Journal:  Heliyon       Date:  2020-04-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.